Abacavir-Lamivudin-Mepha 600 mg/300 mg
Abacavir-Lamivudin-Mepha 600 mg/300 mg is a medicine authorised by Swissmedic under authorisation number 67064. The authorisation holder is Mepha Pharma AG. The medicinal product code is Synthetic medicines and the dispensing category is A: Supplied only against a medical or veterinary prescription that may not be dispensed repeatedly. First authorisation was granted on 04 July 2018 and the authorisation is limited until 01 October 2026. ATC code J05AR02 places the medicine in the group Antivirals for systemic use.
| Authorisation number | 67064 |
|---|---|
| Name | Abacavir-Lamivudin-Mepha 600 mg/300 mg |
| Full name | Abacavir-Lamivudin-Mepha 600 mg/300 mg, Filmtabletten |
| Authorisation holder | Mepha Pharma AG |
| Medicinal product code | Synthetic medicines |
| Dispensing category | A · Prescription, not repeatable |
| ATC code | J05AR02 |
| First authorisation | 04 July 2018 |
| Authorisation validity | 01 October 2026 |
| No. | Name | Dispensing category | Authorisation date |
|---|---|---|---|
| 1 | Abacavir-Lamivudin-Mepha 600 mg/300 mg, Filmtabletten | A | 04 July 2018 |
Scroll the table sideways
| Pack code | Quantity | Unit | ATC | IT code | Dispensing category |
|---|---|---|---|---|---|
| 1 | 30 | Tablette(n) | J05AR02 | 08.03.0. | A |
Scroll the table sideways
Medicines in the same ATC group
Other medicines from this authorisation holder
Frequently asked questions
Is Abacavir-Lamivudin-Mepha 600 mg/300 mg authorised in Switzerland?
Yes. Abacavir-Lamivudin-Mepha 600 mg/300 mg is authorised by Swissmedic under authorisation number 67064, data as of 01 September 2026. The authorisation is limited until 01 October 2026.
Which dispensing category does Abacavir-Lamivudin-Mepha 600 mg/300 mg have?
Abacavir-Lamivudin-Mepha 600 mg/300 mg is in dispensing category A. Supplied only against a medical or veterinary prescription that may not be dispensed repeatedly.
Who is the authorisation holder of Abacavir-Lamivudin-Mepha 600 mg/300 mg?
The authorisation holder is Mepha Pharma AG. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.
Sources
Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.